Literature DB >> 1914373

The effects of oral nifedipine on hepatic blood flow in humans.

W G Reiss1, L A Bauer, J R Horn, B K Zierler, T R Easterling, D E Strandness.   

Abstract

Duplex ultrasonography was used to measure changes in hepatic blood flow in 13 healthy volunteers after they received single doses of 10 mg oral nifedipine and placebo. Blood flow was measured in the hepatic artery and branches of the portal and hepatic veins at baseline and 0.3, 0.6, 1, 1.5, 2, 3, 4, and 5 hours after drug administration. Cardiac output was also measured at baseline and 1, 2, and 3 hours after dosing. Blood flow initially increased in all three vessels 0.6 hour after administration of nifedipine (29%, 56%, and 31% in the hepatic artery, hepatic vein, and portal vein, respectively) compared with placebo. Flow rapidly returned to baseline in the hepatic artery and hepatic vein, whereas it appeared to remain elevated through 3 hours in the portal vein. Nifedipine administration resulted in an increase in cardiac output of 26%, 22%, and 14% above placebo at 1, 2, and 3 hours, respectively. No significant differences were detected in the systolic, diastolic, or mean arterial blood pressures after nifedipine or placebo. This study demonstrates that nifedipine increases hepatic blood flow in a transient nature and systemic hemodynamic parameters do not necessarily reflect specific organ responses. The nifedipine-induced change in blood flow should be considered when nifedipine is coadministered with high-clearance drugs, because systemic availability may be increased.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914373     DOI: 10.1038/clpt.1991.154

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Portal vein thrombosis following laparoscopic surgery in a patient with sickle cell disease.

Authors:  P C H Ng; L Ashari
Journal:  Surg Endosc       Date:  2003-05       Impact factor: 4.584

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Hepatic portal venous flow in patients undergoing tricuspid valve surgery.

Authors:  S F Purkiss; S Fort; T R Graham; P G Mills; C T Lewis
Journal:  Br Heart J       Date:  1994-04

4.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

5.  The influence of nifedipine and captopril on liver blood flow in healthy subjects.

Authors:  J Burggraaf; R C Schoemaker; J M Kroon; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

6.  Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

Authors:  L A Bauer; T O'Sullivan; W G Reiss; J R Horn; K Opheim; D E Strandness; R L Carithers
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

7.  Intravenous nicardipine does not alter hepatic blood flow after orthotopic liver transplant.

Authors:  M Raucoules-Aimé; M Drici; B Goubaux; Y Labib; C Ichai; J Gugenheim; D Grimaud
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.